POZITIV-G® Tablets

No Image Found
Composition:

POZITIV-G1® TABLETS

Each uncoated tablet contains:

  • Pioglitazone Hydrochloride I.P. equivalent to Pioglitazone …………………………………………. 15 mg
  • Glimepiride I.P. ……….. 1 mg
  • Excipients ………………….. q.s.
  • Colour: Yellow Oxide of Iron

 

POZITIV-G2® TABLETS

Each uncoated tablet contains:

  • Pioglitazone Hydrochloride I.P. equivalent to Pioglitazone ………………………………………….… 15 mg
  • Glimepiride I.P. …………. 2 mg
  • Excipients ………......………  q.s.
  • Colour: Red Oxide of Iron

Description

  • Pioglitazone in POZITIV-G2®, POZITIV-G® a member of the thiazolidinedione class of antidiabetic agents, improves glycaemic control by improving insulin sensitivity. It is a highly selective and potent agonist for the peroxisome proliferator- activated receptor-gamma (PPAR-γ). Activation of PPAR-γ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose and lipid metabolism. Pioglitazone stimulates the production of GLUT-4 and it increases the glucose uptake in adipose and muscle cells. In addition,PPAR-γ responsive genes also participate in the regulation of fatty acid metabolism and, thus have shown to confer beneficial effects on cardiovascular functions and lipid parameters Pioglitazone is an "insulin sensitizer" and exerts a direct effect on the mechanism of insulin resistance. These effects not only improve insulin sensitivity and glycaemic control with reduced insulin requirements, but also have potentially favourable effects on other components of the cardiovascular dysmetabolic syndrome. While the action of Glimepiride in POZITIV-G® is attributed to its initial action of stimulation of the beta cells insulin secretion, it has also an insulin-mimetic effect in peripheral tissue possibly mediated by GLUT-4 recruitment. The extra-pancreatic effects may help it to explain the lesser degree of stimulated hyperinsulinemia.
  • Thus, the combination of Pioglitazone and Glimepiride has a synergistic effect, since both agents act to improve glucose tolerance by different, but complementary mechanisms, improving glycaemic control and insulin sensitivity more effectively than treatment with pioglitazone or glimepiride alone.

Indications

  • POZITIV-G® is indicated in Type 2 Diabetic patients who are not controlled by diet and exercise alone or who cannot tolerate metformin.
  • POZITIV-G® is indicated for use in combination with metformin or insulin when triple drug therapy is indicated to achieve glycaemic control.

Dosage

  • Dosage should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose of individual components.
  • It should be given once daily with meals and should be started at a low dose.
  • The usual starting dose is one tablet ofPOZITIV-G® once daily.
  • The dose may be increased to one to three tablets of POZITIV-G® once daily, if adequate response is not observed by 12 weeks.
  • The maximum recommended dose for glimepiride is 8 mg daily. The maximum recommended daily dose for pioglitazone is 45 mg in adults.